1 / 33

SIGN CHD

SIGN CHD. In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with almost 49,000 hospital admissions for CHD and a further 22,050 for cerebrovascular disease. Coronary Heart Disease. SIGN CHD.

phaedra
Download Presentation

SIGN CHD

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with almost 49,000 hospital admissions for CHD and a further 22,050 for cerebrovascular disease. www.isdscotland.org

  2. Coronary Heart Disease

  3. SIGN CHD SIGN is a collaborative network of healthcare professionals and SIGN guidelines are developed by multidisciplinary groups using a standard methodology based on a systematic review of the evidence.

  4. SIGN levels of evidence

  5. SIGN grades of recommendation

  6. SIGN Coronary Heart Disease

  7. SIGN CHD • PREVENTION • STABLE ANGINA • ACUTE CORONARY SYNDROMES • ARRHYTHMIAS • CHRONIC HEART FAILURE

  8. SIGN: Prevention

  9. SIGN CHD: prevention Prevention of CHD - Risk Estimation • Individuals with symptomatic manifestations of cardiovascular disease or diabetes should be considered at high risk (≥ 20% risk over 10 years) of cardiovascular events D • All adults over the age of 40 who have no history of cardiovascular disease or diabetes and who are not being treated for blood pressure or lipid reduction should have their cardiovascular risk estimated at least once every five years D

  10. SIGN CHD : prevention Simvastatin 40 mg/day recommended as part of the management in those patients over age 40 with a 10 year risk of CVS events of > 20% A

  11. Event Clinical benefit over 4.3 years Annual bed days saved Annual cost savings (million) Major vascular 6,217 17,050 £5.9 All cause mortality 2,303 Total 8,520 17,050 £5.9 Potential events avoided and related resources saved from treating 435,000 asymptomatic individuals at high CVD risk with a statin ASCOT-LLA/CARDS

  12. Events Events avoided Annual bed days saved Annual cost savings (million ) Major vascular 9,437 19,770 £6.8 All cause mortality 718 Total 10,155 19,770 £6.8 Potential events and resources saved from treating 95,000 symptomatic individuals with a statin HPS

  13. SIGN has commissioned the development of a score to include social deprivation as a risk variable. ASSIGN tends to classify more people with a positive family history and who are socially deprived as being at high risk. When used in its own host population, it abolished a large social gradient in future CVD victims not identified for preventative treatment by the Framingham score: it therefore improved social equity. http://assign-score.com Heart 2007;93:172-176

  14. SIGN: chronic stable angina

  15. SIGN CHD: Stable Angina • Patients with left main stem disease should undergo coronary artery bypass grafting to improve coronary heart disease prognosis A • Patients with triple vessel disease should be considered for coronary artery bypass grafting to improve coronary heart disease prognosis but where unsuitable be offered percutaneous coronary intervention A • Patients with single or double vessel disease where optimal medical therapy fails to control symptoms should be offered percutaneous intevention or where unsuitable, be considered for coronary bypass surgery A

  16. SIGN: acute coronary syndromes

  17. SIGN CHD: ACS • Patients with ST elevation acute coronary syndrome should be treated immediately with primary percutaneous coronary intervention A • Where primary percutaneous coronary intervention cannot be provided within 90 minutes of diagnosis, patients with ST elevation acute coronary syndrome should receive immediate thrombolytic therapy D • Patients with ST elevation acute coronary syndrome within 6 hours of symptoms who fail to reperfuse following thrombolysis should be considered for rescue percutaneous coronary intervention B

  18. SIGN CHD: ACS • A • ABA In addition to long term aspirin, clopidogrel therapy should be continued for three months in patients with non-ST elevation acute coronary syndromes B

  19. SIGN: Arrhythmias

  20. SIGN CHD: arrhythmias • Patients with impaired LV ejection fraction in NYHA Class I – III after previous myocardial infarction should be considered for ICD therapy A • Patients with spontaneous non-sustained ventricular tachycardia, severely depressed ejection fraction (<0.25) or prolonged QRS duration (>0.12 sec) should be prioritized for ICD implantation B

  21. SIGN Heart Failure

  22. SIGN CHD : heart failure BNP should be checked prior to commencing therapy for suspected heart failure A

  23. SIGN CHD: Heart failure Heart Failure - Interventional procedures In patients in sinus rhythm with drug refractory symptoms of heart failure due to left ventricular systolic function (LVEF < 35%) and who are in NYHA Class III and IV and who have a QRS duration of > 120 m/s, cardiac resynchronisation therapy (CRT) should be considered A

  24. SIGN CHD: Heart failure Heart Failure - Discharge planning • Comprehensive discharge planning to ensure links with post discharge services should be available to all those with symptomatic heart failure. A nurse-led, home based element should be included A • Telephone follow-up by specialised heart failure nurses should be considered for patients with stable heart failure. Nurses should have the ability to alter diuretic dose, telephone schedules and recommend emergency/non-scheduled medical contact A

  25. SIGN CHD What are the potential clinical events avoided by implementation?

  26. Recommendation by guideline Mortalityavoided over 5 years Events avoided over 5 years Bed days saved per year Savings per year(£ million) Statins – primary prevention 2,678 7,229 17,052 5.9 Statins – secondary prevention 718 9,437 19,770 6.8 Antihypertensive drugs 950 2,761 9,108 2.5 Prevention - other 750 2,672 5,414 2.0 Prevention - total 5,096 22,099 51,344 17.2 Acute Coronary Syndromes guideline 896 2,176 2,394 1.2 Arrhythmia and Heart Failure guidelines 1,232 2,851 7,074 2.3 Total events 7,224 27,126 60,812 20.7 SIGN CHD implementation benefits

  27. Cost (£ million) Year 1 Year 6 ACS 5 (5) 5 (5) Arrhythmias 4 (5) 4 (5) Heart Failure 7 (7) 7 (7) Prevention 25 (27) 54 (62) Total 41 (44) 70 (79) Estimated annual cost of implementing key recommendations by guideline

  28. SIGN CHD The recommendations on statins and hypertension account for over 90% of the costs and the savings

  29. SIGN CHD Over the next five years, it is estimated that over 7,200 premature deaths from CVD and over 27,000 vascular events could be avoided. This is equivalent to a 9% reduction from the current CVD mortality rate and an 8% reduction from the current CVD event rate.

More Related